A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

For advanced and metastatic prostate cancer, androgen deprivation therapy (ADT) is the mainstay of treatment. Awareness of the potential bone-health complications consequent to ADT use is increasing. Many studies have shown that prolonged ADT leads to significant bone loss and increased fracture risk that negatively affect quality of life. Clinical practice guidelines for preserving bone health in men with prostate cancer on ADT vary across Canada. This paper reviews recent studies on bone health in men with prostate cancer receiving ADT and the current evidence regarding bone-health monitoring and management in reference to Canadian provincial guidelines. Based on this narrative review, we provide general bone-health management recommendations for men with prostate cancer receiving ADT. [ABSTRACT FROM AUTHOR]